User profiles for "author:Toni Choueiri"
Toni ChoueiriDana-Farber Cancer Institute Verified email at dfci.harvard.edu Cited by 111158 |
[HTML][HTML] Post-acute COVID-19 syndrome
A Nalbandian, K Sehgal, A Gupta, MV Madhavan… - Nature medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen
responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in …
responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in …
Systemic therapy for metastatic renal-cell carcinoma
TK Choueiri, RJ Motzer - New England Journal of Medicine, 2017 - Mass Medical Soc
Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …
Targeting the HIF2–VEGF axis in renal cell carcinoma
TK Choueiri, WG Kaelin Jr - Nature medicine, 2020 - nature.com
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …
[HTML][HTML] Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …
with encouraging overall survival in uncontrolled studies involving previously treated …
[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
[PDF][PDF] The immune landscape of cancer
We performed an extensive immunogenomic analysis of more than 10,000 tumors
comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer …
comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer …
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Background Data on patients with COVID-19 who have cancer are lacking. Here we
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …
[HTML][HTML] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
J Bellmunt, R De Wit, DJ Vaughn… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced urothelial carcinoma that progresses after platinum-
based chemotherapy have a poor prognosis and limited treatment options. Methods In this …
based chemotherapy have a poor prognosis and limited treatment options. Methods In this …
[HTML][HTML] Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
TK Choueiri, T Powles, M Burotto… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …
[HTML][HTML] Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
Background Lenvatinib in combination with pembrolizumab or everolimus has activity
against advanced renal cell carcinoma. The efficacy of these regimens as compared with …
against advanced renal cell carcinoma. The efficacy of these regimens as compared with …